Atlas Trials

PIK3CA-Related Overgrowth Spectrum (PROS)

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch PIK3CA-Related Overgrowth Spectrum (PROS)

RecordFirmDate
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (NCT04980833)Novartis Pharmaceuticals2022-01-27
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (NCT04589650)Novartis Pharmaceuticals2021-04-19
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (NCT04285723)Novartis Pharmaceuticals2020-06-09
Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation (NCT02428296)National Human Genome Research Institute (NHGRI)2015-04-23
Managed Access Programs for BYL719, Alpelisib (NCT04085653)Novartis Pharmaceuticals
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies (NCT03317366)ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Track PIK3CA-Related Overgrowth Spectrum (PROS) automatically

Every clearance here is in the API, with alerts when new ones post.